(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three most active and biggest winners today are CytomX Therapeutics, Celsius Holdings, and Cemtrex.

Rank Financial Asset Price Change Updated (EST)
1 CytomX Therapeutics (CTMX) 1.78 16.34% 2022-05-11 07:23:13
2 Celsius Holdings (CELH) 46.84 13.39% 2022-05-11 14:48:41
3 Cemtrex (CETXP) 2.06 13.19% 2022-05-10 23:15:06
4 Celcuity (CELC) 6.96 11.72% 2022-05-10 23:12:06
5 CLPS Incorporation (CLPS) 1.84 11.52% 2022-05-11 03:10:05
6 Cemtrex (CETX) 0.31 9.81% 2022-05-10 23:14:05
7 CRISPR Therapeutics AG (CRSP) 47.31 9.44% 2022-05-11 07:07:06
8 Corvus Pharmaceuticals (CRVS) 1.22 8.93% 2022-05-11 07:08:06
9 Citius Pharmaceuticals (CTXR) 1.02 8.31% 2022-05-11 07:42:14
10 Electronic Arts (EA) 120.46 7.94% 2022-05-11 14:57:23

The three most active and biggest losers today are Inovio Pharmaceuticals, Coinbase, and Fiverr.

Rank Financial Asset Price Change Updated (EST)
1 Inovio Pharmaceuticals (INO) 1.81 -27.51% 2022-05-11 14:43:57
2 Coinbase (COIN) 53.02 -27.36% 2022-05-11 14:53:42
3 Fiverr (FVRR) 30.26 -25.96% 2022-05-11 14:53:03
4 MicroStrategy (MSTR) 168.81 -25.15% 2022-05-11 14:58:23
5 TherapeuticsMD (TXMD) 3.45 -25% 2022-05-11 14:51:20
6 CarGurus (CARG) 23.01 -22.86% 2022-05-10 21:11:06
7 American Public Education (APEI) 13.72 -22.79% 2022-05-11 14:55:31
8 Arcturus Therapeutics (ARCT) 12.95 -21.89% 2022-05-11 14:46:02
9 Kodak (KODK) 3.86 -21.81% 2022-05-11 14:59:50
10 DISH Network (DISH) 17.30 -20.48% 2022-05-11 14:57:10

Most Active Winners today

1. CytomX Therapeutics (CTMX) – 16.34%

CytomX Therapeutics, Inc. is an American oncology-focused, biopharmaceutical firm. It develops anti-cancer therapeutics using its Probody platform. CX-2009 is a product candidate that uses its Probody technology platform to develop anti-CTLA-4 Probody drugs. It is currently in Phase II clinical trial for treatment of breast carcinoma. CX-2043 is a conditionally activated ADC that targets epithelial cells adhesion molecules. CX-904 is a conditionally activated epidermal Growth Factor receptor to treat solid tumors. To develop Probody therapeutics, the company collaborates strategically with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., Astellas Pharma Inc. CytomX Therapeutics, Inc. is located in South San Francisco, California.

NASDAQ ended the session with CytomX Therapeutics jumping 16.34% to $1.78 on Wednesday while NASDAQ dropped 3.18% to $11,364.24.

Volume

Today’s last reported volume for CytomX Therapeutics is 1926320 which is 87.15% above its average volume of 1029260.

CytomX Therapeutics’s last close was $1.78, 80.11% under its 52-week high of $8.95.

CytomX Therapeutics’s Sales

CytomX Therapeutics’s sales growth is 49.7% for the present quarter and 26.4% for the next. The company’s growth estimates for the present quarter is 12.5% and a drop 30.8% for the next.

CytomX Therapeutics’s Revenue

Year-on-year quarterly revenue growth declined by 1.1%, now sitting on 66.22M for the twelve trailing months.

CytomX Therapeutics’s Stock Yearly Top and Bottom Value

CytomX Therapeutics’s stock is valued at $1.78 at 17:32 EST, way below its 52-week high of $8.95 and way above its 52-week low of $1.51.

CytomX Therapeutics’s Moving Average

CytomX Therapeutics’s value is way under its 50-day moving average of $2.67 and way under its 200-day moving average of $4.57.

More news about CytomX Therapeutics.

2. Celsius Holdings (CELH) – 13.39%

Celsius Holdings, Inc. markets, distributes, sells and promotes functional, calorie-burning, fitness drinks in the United States as well as internationally. It offers a variety of beverages, such as carbonated orange and wild berry, cola and grape, kiwi guava and watermelon. Celsius Heat is a nutritional supplement that contains carbonated flavorings such as orange jack’d and blueberry pomegranate. Blueberry pomegranate. strawberry dragonfruit. tangerine grapefruit. It distributes products via direct-store distribution distributors as well as retailers that include supermarkets and convenience stores as well as drug and nutritional stores and mass merchants. In January 2007, Celsius Holdings, Inc. was established. Celsius Holdings, Inc., was established in 2004. It is located in Boca Raton, Florida.

NASDAQ ended the session with Celsius Holdings jumping 13.39% to $46.84 on Wednesday, after five consecutive sessions in a row of losses. NASDAQ fell 3.18% to $11,364.24, following the last session’s upward trend on what was a very down trend trading session today.

Volume

Today’s last reported volume for Celsius Holdings is 3867010 which is 333.92% above its average volume of 891170.

Celsius Holdings’s last close was $41.31, 62.52% below its 52-week high of $110.22.

Celsius Holdings’s Sales

Celsius Holdings’s sales growth is 151.4% for the ongoing quarter and 108.3% for the next. The company’s growth estimates for the ongoing quarter and the next is 100% and 400%, respectively.

Celsius Holdings’s Revenue

Year-on-year quarterly revenue growth grew by 157.6%, now sitting on 245.68M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Celsius Holdings’s stock is considered to be overbought (>=80).

Celsius Holdings’s Stock Yearly Top and Bottom Value

Celsius Holdings’s stock is valued at $46.84 at 17:32 EST, way under its 52-week high of $110.22 and way higher than its 52-week low of $39.45.

Celsius Holdings’s Moving Average

Celsius Holdings’s value is way below its 50-day moving average of $54.72 and way below its 200-day moving average of $69.58.

More news about Celsius Holdings.

3. Cemtrex (CETXP) – 13.19%

Cemtrex, Inc. is a US-based technology company. Two segments of the company are Advanced Technologies and Industrial Services. Advanced Technologies provides Internet of Things products, smart devices, under SmartDesk, for mobile, web and virtual augmented reality. It also offers security and surveillance solutions. The segment offers web-based video surveillance systems as well as analytics-based recognition and cameras. It also provides access control systems to secure and monitor industrial and commercial buildings, federal prisons and hospitals, universities and schools. Industrial Services provides single-source solutions for in-plant maintenance, rigging and equipment relocation. It also installs precision machinery in various markets including automotive, printing and graphics and chemical. The firm was previously known as Diversified American Holding, Inc., but changed its name in December 2004 to Cemtrex, Inc. Cemtrex, Inc. is an American company that was founded in 1998. Its headquarters are in Brooklyn, New York.

NASDAQ ended the session with Cemtrex rising 13.19% to $2.06 on Wednesday, after two sequential sessions in a row of gains. NASDAQ dropped 3.18% to $11,364.24, following the last session’s upward trend on what was a very negative trend exchanging session today.

Volume

Today’s last reported volume for Cemtrex is 116544 which is 126.61% above its average volume of 51428.

Cemtrex’s last close was $2.06, 44.62% below its 52-week high of $3.72.

Cemtrex’s Revenue

Year-on-year quarterly revenue growth grew by 20.8%, now sitting on 44.97M for the twelve trailing months.

Cemtrex’s Stock Yearly Top and Bottom Value

Cemtrex’s stock is valued at $2.06 at 17:32 EST, way below its 52-week high of $3.72 and way higher than its 52-week low of $0.60.

Cemtrex’s Moving Average

Cemtrex’s worth is way above its 50-day moving average of $1.42 and way above its 200-day moving average of $1.76.

More news about Cemtrex.

4. Celcuity (CELC) – 11.72%

Celcuity Inc. is a biotechnology company in clinical stages. It discovers sub-types of cancer and offers therapeutic options to patients with cancer. CELsignia’s diagnostic platform, which uses patient-derived tumor cells as a source of information to determine the abnormal cell process that is driving the patient’s disease and then prescribe targeted therapies. CELsignia MP, which is a laboratory-developed test measuring HER2, cMet and PI3K activity in breast tumor cells and ovarian cancer cells, has also been developed by the company. Celcuity Inc. is located in Minneapolis, Minnesota.

NASDAQ ended the session with Celcuity jumping 11.72% to $6.96 on Wednesday while NASDAQ slid 3.18% to $11,364.24.

Volume

Today’s last reported volume for Celcuity is 66084 which is 25.37% above its average volume of 52708.

Celcuity’s last close was $6.96, 78.92% under its 52-week high of $33.01.

The company’s growth estimates for the ongoing quarter is a negative 104% and positive 47.7% for the next.

Celcuity’s Stock Yearly Top and Bottom Value

Celcuity’s stock is valued at $6.96 at 17:32 EST, way under its 52-week high of $33.01 and way above its 52-week low of $5.94.

Celcuity’s Moving Average

Celcuity’s value is way under its 50-day moving average of $8.07 and way under its 200-day moving average of $14.20.

More news about Celcuity.

5. CLPS Incorporation (CLPS) – 11.52%

CLPS Incorporation offers information technology and consulting to financial institutions in China, the People’s Republic of China, and around the world. The company offers IT consulting in the credit card industry, including credit card applications, account setups, authorization, activation, settlement, promotion, point system and anti-fraud. It also provides reporting and statement services. The company also provides banking services, including business analysis, system design, development, testing, system maintenance, and operation support; and services in loans, deposit, general ledger, wealth management, debit card, anti-money-laundering, statement and reporting, and risk management, as well as architecture consulting services for banking systems, and online and mobile banking. It also offers services in wealth management, ecommerce solutions on online platforms, trans-border ecommerce, logistics and back-end tech, including big data analysis, intelligent decision-making, driving, auto control and other AI-driven technologies for the automotive sector. The company also offers IT consulting services for its clients, including in the automotive, banking, wealth management and e-commerce industries. It also provides software development, maintenance and testing services. It also offers the CLPS Virtual Banking platform which is a platform that trains IT talent; recruits and headshunts; as well as training and fee-for service services. The company sells third-party and product software. It was established in Hong Kong in 2005.

NASDAQ ended the session with CLPS Incorporation rising 11.52% to $1.84 on Wednesday while NASDAQ fell 3.18% to $11,364.24.

Volume

Today’s last reported volume for CLPS Incorporation is 36190 which is 28.65% below its average volume of 50723.

CLPS Incorporation’s last close was $1.84, 64.95% under its 52-week high of $5.25.

CLPS Incorporation’s Revenue

Year-on-year quarterly revenue growth grew by 30.2%, now sitting on 143.67M for the twelve trailing months.

CLPS Incorporation’s Stock Yearly Top and Bottom Value

CLPS Incorporation’s stock is valued at $1.84 at 17:33 EST, way under its 52-week high of $5.25 and way higher than its 52-week low of $1.61.

CLPS Incorporation’s Moving Average

CLPS Incorporation’s value is below its 50-day moving average of $1.96 and way below its 200-day moving average of $2.54.

More news about CLPS Incorporation.

6. Cemtrex (CETX) – 9.81%

Cemtrex, Inc. is a US-based technology company. Two segments of the company are Advanced Technologies and Industrial Services. Advanced Technologies provides Internet of Things products, smart devices, under SmartDesk, for mobile, web and virtual augmented reality. It also offers security and surveillance solutions. The segment offers web-based video surveillance systems as well as analytics-based recognition and cameras. It also provides access control systems to secure and monitor industrial and commercial buildings, federal prisons and hospitals, universities and schools. Industrial Services provides single-source solutions for in-plant maintenance, rigging and equipment relocation. It also installs precision machinery in several industrial markets, including automotive, printing and graphics and chemical. Cemtrex, Inc. was previously known as Diversified American Holding, Inc. Cemtrex, Inc. is an American company that was founded in 1998. Its headquarters are in Brooklyn, New York.

NASDAQ ended the session with Cemtrex rising 9.81% to $0.31 on Wednesday, following the last session’s upward trend. NASDAQ dropped 3.18% to $11,364.24, following the last session’s upward trend on what was a very bearish trend trading session today.

Volume

Today’s last reported volume for Cemtrex is 823770 which is 128.75% above its average volume of 360108.

Cemtrex’s last close was $0.31, 87.89% under its 52-week high of $2.56.

Cemtrex’s Revenue

Year-on-year quarterly revenue growth grew by 20.8%, now sitting on 44.97M for the twelve trailing months.

Cemtrex’s Stock Yearly Top and Bottom Value

Cemtrex’s stock is valued at $0.31 at 17:33 EST, way under its 52-week high of $2.56 and way above its 52-week low of $0.27.

Cemtrex’s Moving Average

Cemtrex’s worth is way under its 50-day moving average of $0.55 and way under its 200-day moving average of $0.92.

More news about Cemtrex.

7. CRISPR Therapeutics AG (CRSP) – 9.44%

CRISPR Therapeutics AG is a company that specializes in gene editing. It focuses its efforts on creating transformative gene-based treatments for severe human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. The company has therapeutic programs for a variety of diseases, such as hemoglobinopathies and regenerative medicine. The company’s lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient’s hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. CTX110 is a donor-derived, gene-edited allogeneic allogeneic allogeneic CR-T therapy that targets cluster of differentiation 19 negative malignancies. Allogeneic CR-T programs comprise CTX120 which targets B-cell maturation and CTX130 to treat solid tumors. The company also develops in-vivo and other genetic diseases programs for diabetes, glycogen storage disorder Ia, Duchenne muscular dysfunction, myotonic hypertrophic syndrome type 1 and cystic fibrillosis. Strategic partnerships include Bayer Healthcare LLC, Vertex Pharmas Incorporated, ViaCyte, Inc., Nkarta, Inc., Capsida Biotherapeutics, and Bayer Healthcare LLC. Inception Genomics AG was the company’s former name. In April 2014, CRISPR Therapeutics AG took over that title. CRISPR Therapeutics AG is located in Zug, Switzerland. It was established in 2013.

NASDAQ ended the session with CRISPR Therapeutics AG jumping 9.44% to $47.31 on Wednesday while NASDAQ fell 3.18% to $11,364.24.

Volume

Today’s last reported volume for CRISPR Therapeutics AG is 2325360 which is 61.87% above its average volume of 1436480.

CRISPR Therapeutics AG’s last close was $47.31, 72.13% below its 52-week high of $169.76.

The company’s growth estimates for the ongoing quarter and the next is a negative 121.6% and a negative 24.6%, respectively.

CRISPR Therapeutics AG’s Revenue

Year-on-year quarterly revenue growth grew by 3386.2%, now sitting on 914.96M for the twelve trailing months.

CRISPR Therapeutics AG’s Stock Yearly Top and Bottom Value

CRISPR Therapeutics AG’s stock is valued at $47.31 at 17:33 EST, way below its 52-week high of $169.76 and higher than its 52-week low of $43.05.

CRISPR Therapeutics AG’s Moving Average

CRISPR Therapeutics AG’s worth is way below its 50-day moving average of $59.44 and way under its 200-day moving average of $83.87.

More news about CRISPR Therapeutics AG.

8. Corvus Pharmaceuticals (CRVS) – 8.93%

Corvus Pharmaceuticals, Inc. is a biopharmaceutical company at the clinical stage. It focuses its efforts on developing and marketing immuno-oncology treatments. CPI006, an antiCD73 monoclonal antibody that is being developed, is currently in phase I/Ib clinical trials. It inhibits the production adenosine, activates various immune cells and is part of Phase III clinical trials of CPI006 for COVID-19. CPI-818 is a covalent inhibitor to ITK and is currently in Phase I/Ib clinical trials. Ciforadenant is an oral small-molecule antagonist to the A2A receptor, which is being developed by the company. This is an immuno checkpoint. CPI-182, which blocks neutrophil migration and function, as well as myeloid-derived suppressor cells, are its preclinical stage products. CPI-935 is an antagonist of the adenosine A2B A receptor to stop fibrosis. Angel Pharmaceuticals has been a strategic partner of Corvus Pharmaceuticals, Inc. for developing its targeted investigational medicine pipeline. It was founded in 2014. The company is located in Burlingame in California.

NASDAQ ended the session with Corvus Pharmaceuticals rising 8.93% to $1.22 on Wednesday, following the last session’s upward trend. NASDAQ fell 3.18% to $11,364.24, following the last session’s upward trend on what was a very down trend exchanging session today.

Volume

Today’s last reported volume for Corvus Pharmaceuticals is 286747 which is 15.15% above its average volume of 249020.

Corvus Pharmaceuticals’s last close was $1.22, 87.21% below its 52-week high of $9.54.

The company’s growth estimates for the present quarter and the next is 39.3% and 8.3%, respectively.

Corvus Pharmaceuticals’s Stock Yearly Top and Bottom Value

Corvus Pharmaceuticals’s stock is valued at $1.22 at 17:34 EST, way under its 52-week high of $9.54 and way above its 52-week low of $1.10.

Corvus Pharmaceuticals’s Moving Average

Corvus Pharmaceuticals’s worth is way under its 50-day moving average of $1.54 and way under its 200-day moving average of $2.75.

More news about Corvus Pharmaceuticals.

9. Citius Pharmaceuticals (CTXR) – 8.31%

Citius Pharmaceuticals, Inc. is a specialty pharmaceutical firm that develops and markets critical care products. It focuses on the creation and marketing of anti-infective products for adjunct cancer care, prescription drugs, and mesenchymal and stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc., was established in Cranford, New Jersey in 2007.

NASDAQ ended the session with Citius Pharmaceuticals rising 8.31% to $1.02 on Wednesday while NASDAQ dropped 3.18% to $11,364.24.

Volume

Today’s last reported volume for Citius Pharmaceuticals is 1344230 which is 29.8% below its average volume of 1915100.

Citius Pharmaceuticals’s last close was $1.02, 77.63% under its 52-week high of $4.56.

Citius Pharmaceuticals’s Stock Yearly Top and Bottom Value

Citius Pharmaceuticals’s stock is valued at $1.02 at 17:34 EST, way below its 52-week high of $4.56 and way above its 52-week low of $0.90.

Citius Pharmaceuticals’s Moving Average

Citius Pharmaceuticals’s worth is way under its 50-day moving average of $1.46 and way under its 200-day moving average of $1.71.

More news about Citius Pharmaceuticals.

10. Electronic Arts (EA) – 7.94%

Electronic Arts Inc. creates, markets and publishes content and games for mobile devices, tablets, smartphones, PCs and other gaming consoles. The company publishes and develops services and games in a variety of genres including sports, first person shooter, action and role-playing. It also licenses games from other brands, like FIFA, Madden NFL and Star Wars. The company also offers advertising services and licences its games for distribution and hosting to third-parties. It markets its services and games through digital distribution channels and retail channels. The company also sells directly to specialty shops, mass-market retailers and distributors. KLab Inc. is its strategic partner for game design and operations. Electronic Arts Inc. was established in 1982. It is located in Redwood City in California.

NASDAQ ended the session with Electronic Arts rising 7.94% to $120.46 on Wednesday while NASDAQ fell 3.18% to $11,364.24.

Volume

Today’s last reported volume for Electronic Arts is 7295710 which is 258.92% above its average volume of 2032660.

Electronic Arts’s last close was $111.60, 25.07% under its 52-week high of $148.93.

The company’s growth estimates for the present quarter and the next is 5.6% and 20.3%, respectively.

Electronic Arts’s Revenue

Year-on-year quarterly revenue growth grew by 58.6%, now sitting on 6.4B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Electronic Arts’s stock is considered to be overbought (>=80).

Electronic Arts’s Stock Yearly Top and Bottom Value

Electronic Arts’s stock is valued at $120.46 at 17:34 EST, way under its 52-week high of $148.93 and above its 52-week low of $114.39.

Electronic Arts’s Moving Average

Electronic Arts’s worth is below its 50-day moving average of $124.59 and below its 200-day moving average of $133.04.

More news about Electronic Arts.

Most Active Losers Today

1. Inovio Pharmaceuticals (INO) – -27.51%

Inovio Pharmaceuticals, Inc. is a biotechnology firm that focuses on developing, commercializing, and marketing DNA medicines. These DNA medicines are used to cure, prevent, or treat diseases such as cancer, human papillomavirus, and other infectious diseases. The SynCon immunotherapy design of Inovio Pharmaceuticals, Inc. can break the immune system’s tolerance for cancerous cells. It also facilitates cross-strain protection from unmatched or matched pathogens. It is currently involved in planning and conducting clinical trials of DNA medicines to treat HPV-associated diseases, including anal and cervical vulvar dysplasia, HPV-associated cervical cancers and other HPV related disorders such as Ebola, Middle East Respiratory syndrome (MERS), Lassa virus, Zika virus, COVID-19 virus, and coronavirus. ApolloBio Corp. or AstraZeneca PLC, Beijing Advaccine Biotechnology Co. and The Bill & Melinda Gates Foundation are its partners and collaborators. To support the investigational DNA vaccine, INO-4800 is being tested in Phase 1 clinical trials for COVID-19. The company has also signed an agreement with Richter-Helm BioLogics GmbH & Co. KG. Plymouth Meeting is the headquarters of this company, which was established in 1979.

NASDAQ ended the session with Inovio Pharmaceuticals sliding 27.51% to $1.81 on Wednesday, following the last session’s upward trend. NASDAQ dropped 3.18% to $11,364.24, following the last session’s upward trend on what was a very down trend exchanging session today.

Volume

Today’s last reported volume for Inovio Pharmaceuticals is 15603000 which is 241.99% above its average volume of 4562360.

Inovio Pharmaceuticals’s last close was $2.49, 75.9% below its 52-week high of $10.33.

Inovio Pharmaceuticals’s Sales

Inovio Pharmaceuticals’s sales growth is a negative 49.1% for the present quarter and a decline by 19.1% for the next. The company’s growth estimates for the current quarter and the next is a negative 128.6% and a negative 7.4%, respectively.

Inovio Pharmaceuticals’s Revenue

Year-on-year quarterly revenue growth grew by 23.5%, now sitting on 6.52M for the twelve trailing months.

Inovio Pharmaceuticals’s Stock Yearly Top and Bottom Value

Inovio Pharmaceuticals’s stock is valued at $1.81 at 17:34 EST, way below its 52-week low of $2.64.

Inovio Pharmaceuticals’s Moving Average

Inovio Pharmaceuticals’s worth is way below its 50-day moving average of $3.30 and way below its 200-day moving average of $5.87.

More news about Inovio Pharmaceuticals.

2. Coinbase (COIN) – -27.36%

NASDAQ ended the session with Coinbase dropping 27.36% to $53.02 on Wednesday, after four successive sessions in a row of losses. NASDAQ dropped 3.18% to $11,364.24, following the last session’s upward trend on what was a very negative trend exchanging session today.

Volume

Today’s last reported volume for Coinbase is 64154500 which is 1103.2% above its average volume of 5332000.

News about Coinbase today

  • Coinbase stock collapse might not be over as crypto winter is coming. According to today’s article on FXStreet, "I think it’s worth just addressing the elephant in the room, which is that, of course, the broader markets are down," said Coinbase CEO and co-founder Brian Armstrong. ", "This signifies that executives focused on the crypto market day in and day out view this summer as a crypto winter, which should spell more poor results for Coinbase going forward."

Previous days news about Coinbase

  • Coinbase stock keeps sliding. According to The Wall Street Journal on Tuesday, 10 May, "The largest U.S. exchange, Coinbase Global Inc. has tumbled 79% from its all-time high in November 2021 when bitcoin reached record levels of $67,802.30. "

More news about Coinbase.

3. Fiverr (FVRR) – -25.96%

NYSE ended the session with Fiverr sliding 25.96% to $30.26 on Wednesday while NYSE slid 0.82% to $14,902.14.

Volume

Today’s last reported volume for Fiverr is 5945460 which is 486.92% above its average volume of 1012990.

Fiverr’s last close was $63.28, 81.17% below its 52-week high of $336.00.

Fiverr’s Sales

Fiverr’s sales growth is 35.8% for the current quarter and 30.2% for the next. The company’s growth estimates for the current quarter and the next is a negative 108.3% and a negative 100%, respectively.

Fiverr’s Revenue

Year-on-year quarterly revenue growth grew by 89.2%, now sitting on 189.51M for the twelve trailing months.

Fiverr’s Stock Yearly Top and Bottom Value

Fiverr’s stock is valued at $30.26 at 17:34 EST, way below its 52-week low of $152.27.

Fiverr’s Moving Average

Fiverr’s worth is way under its 50-day moving average of $181.37 and way below its 200-day moving average of $197.07.

More news about Fiverr.

4. MicroStrategy (MSTR) – -25.15%

MicroStrategy Incorporated offers enterprise analytics software and other services around the world. MicroStrategy 2020 is an enterprise platform that provides analytics across multiple devices. It allows analysts and data scientists seamless access to trust-governed data within their tool. MicroStrategy support is available to customers in order to help them achieve system availability, uptime and improve their overall user experience. This includes proactive product support and highly responsive technical troubleshooting. It also offers MicroStrategy Consulting, which provides architecture and implementation services that help customers quickly achieve results and maximize returns on their investment. It provides services via channel partners and enterprise sales. The company serves companies in a variety of sectors, such as retail, consulting and technology. It was established in Tysons Corner in Virginia in 1989.

NASDAQ ended the session with MicroStrategy falling 25.15% to $168.81 on Wednesday while NASDAQ slid 3.18% to $11,364.24.

Volume

Today’s last reported volume for MicroStrategy is 3060060 which is 546.99% above its average volume of 472968.

MicroStrategy’s last close was $225.52, 74.7% under its 52-week high of $891.38.

MicroStrategy’s Sales

MicroStrategy’s sales growth is 1.4% for the current quarter and 15% for the next. The company’s growth estimates for the present quarter is 292.3% and a drop 11% for the next.

MicroStrategy’s Revenue

Year-on-year quarterly revenue growth grew by 0.5%, now sitting on 507.57M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

MicroStrategy’s stock is considered to be overbought (>=80).

MicroStrategy’s Stock Yearly Top and Bottom Value

MicroStrategy’s stock is valued at $168.81 at 17:35 EST, way under its 52-week low of $282.55.

MicroStrategy’s Moving Average

MicroStrategy’s value is way below its 50-day moving average of $431.08 and way under its 200-day moving average of $568.23.

More news about MicroStrategy.

5. TherapeuticsMD (TXMD) – -25%

TherapeuticsMD, Inc. is a United States women’s health company. The company provides IMVEXXY, a treatment for moderate-to severe dyspareunia, and BIJUVA which is a bioidentical hormonal therapy combination of 17AY-estradiol, progesterone, for moderate to severe vasomotor symptoms. TX-015HR is a transdermal patch candidate that contains progesterone and estradiol. TX-009HR is the company’s clinical product. It contains an oral progesterone/estradiol formula. The company also produces and distributes generic and branded prescription prenatal vitamins under the vitaTrue and vitaMedMD brands. It sells prescription hormone therapy drugs and prenatal vitamins to both wholesale and retail pharmacie distributors. TherapeuticsMD, Inc., is located in Boca Raton, Florida.

NASDAQ ended the session with TherapeuticsMD dropping 25% to $3.45 on Wednesday, after three successive sessions in a row of losses. NASDAQ slid 3.18% to $11,364.24, following the last session’s upward trend on what was a very down trend trading session today.

Volume

Today’s last reported volume for TherapeuticsMD is 1068860 which is 437.19% above its average volume of 198970.

TherapeuticsMD’s last close was $4.60, 67.27% higher than its 52-week high of $2.75.

TherapeuticsMD’s Sales

TherapeuticsMD’s sales growth is 33.7% for the present quarter and 29.3% for the next. The company’s growth estimates for the ongoing quarter and the next is 16.7% and 40%, respectively.

TherapeuticsMD’s Revenue

Year-on-year quarterly revenue growth grew by 114.9%, now sitting on 84.79M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

TherapeuticsMD’s stock is considered to be oversold (<=20).

TherapeuticsMD’s Stock Yearly Top and Bottom Value

TherapeuticsMD’s stock is valued at $3.45 at 17:35 EST, way above its 52-week high of $2.75.

TherapeuticsMD’s Moving Average

TherapeuticsMD’s value is way higher than its 50-day moving average of $0.66 and way above its 200-day moving average of $1.00.

More news about TherapeuticsMD.

6. CarGurus (CARG) – -22.86%

CarGurus, Inc. is an online marketplace that connects buyers and sellers for new and used automobiles in the United States as well as internationally. It offers consumers an automotive marketplace online where they can find new and used cars from dealers as well as the ability to sell their vehicle in the United States. The marketplace allows dealers to connect with a wide range of consumers who are educated and interested. It operates two online marketplaces, one under the CarGurus name in Canada and one in the United Kingdom. The Autolist and PistonHeads marketplaces are independent brands within the United States and United Kingdom. CarGurus, Inc., was established in 2005. It is located in Cambridge, Massachusetts.

NASDAQ ended the session with CarGurus falling 22.86% to $23.01 on Wednesday while NASDAQ slid 3.18% to $11,364.24.

Volume

Today’s last reported volume for CarGurus is 6658710 which is 365.53% above its average volume of 1430340.

CarGurus’s last close was $23.01, 54.01% under its 52-week high of $50.03.

The company’s growth estimates for the present quarter is a negative 7.3% and positive 10.5% for the next.

CarGurus’s Revenue

Year-on-year quarterly revenue growth grew by 123.9%, now sitting on 951.37M for the twelve trailing months.

CarGurus’s Stock Yearly Top and Bottom Value

CarGurus’s stock is valued at $23.01 at 17:35 EST, way under its 52-week high of $50.03 and way higher than its 52-week low of $20.15.

CarGurus’s Moving Average

CarGurus’s value is way under its 50-day moving average of $39.55 and way under its 200-day moving average of $34.72.

Previous days news about CarGurus

  • Cargurus beats Q1 expectations, but stock falls. According to MarketWatch on Monday, 9 May, "Shares of CarGurus Inc. dropped 12% in the extended session Monday after the online car marketplace reported first-quarter earnings and sales that beat Wall Street expectations, but called for lower-than-expected adjusted per-share earnings for its second quarter. "

More news about CarGurus.

7. American Public Education (APEI) – -22.79%

American Public Education, Inc. and its affiliates offer online as well campus-based postsecondary education. American Public Education is one segment of the company. Hondros College of Nursing is another. The company offers 121 degrees and 111 certificates in a variety of fields, such as business administration, security, military studies and intelligence as well as homeland security and national security. It also offers a diploma in practical nursing and an associate in nursing degree. American Public Education, Inc., was established in 1991. It is located in Charles Town, West Virginia.

NASDAQ ended the session with American Public Education sliding 22.79% to $13.72 on Wednesday while NASDAQ slid 3.18% to $11,364.24.

Volume

Today’s last reported volume for American Public Education is 145073 which is 109.02% above its average volume of 69405.

American Public Education’s last close was $17.77, 42.79% under its 52-week high of $31.06.

American Public Education’s Sales

American Public Education’s sales growth is 77.5% for the ongoing quarter and 94.7% for the next. The company’s growth estimates for the present quarter is a negative 61.2% and positive 633.3% for the next.

American Public Education’s Revenue

Year-on-year quarterly revenue growth grew by 24.2%, now sitting on 350.71M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

American Public Education’s stock is considered to be overbought (>=80).

American Public Education’s Stock Yearly Top and Bottom Value

American Public Education’s stock is valued at $13.72 at 17:36 EST, way under its 52-week low of $16.97.

American Public Education’s Moving Average

American Public Education’s worth is way under its 50-day moving average of $21.38 and way under its 200-day moving average of $23.37.

More news about American Public Education.

8. Arcturus Therapeutics (ARCT) – -21.89%

Arcturus Therapeutics Holdings Inc. is an RNA medicine company that specializes in the treatment of respiratory and liver diseases. The company engages in the discovery and development of RNA medicines, including the production of RNA drug substance and nanoparticle-formulated drug product; and development of infectious disease vaccines using its Self-Transcribing and Replicating RNA (STARR) technology. LUNAR, a preclinical drug development program for ornithine transcarbamylase deficiency (OTC), is currently developing mRNA molecules to treat the condition. LUNAR and LUNAR CF are programs that develop mRNA compounds that replace cystic fibrosis’ transmembrane conductance regulate (CFTR) proteins in patients with cystic fibrosis. LUNAR and LUNAR MD are internal research programs that target validation of several pipeline LUNAR mRNA programs. LUNAR, nucleic acid and related technologies are owned by the company. Patent applications and portfolios of patents have been filed in 182 countries, including China, Japan, Europe and Japan. To develop rare diseases, it has formed partnerships with Ultragenyx Pharmaceutical, Inc.; Millennium Pharmaceuticals, Inc., Takeda to create a nucleic-acid-based therapeutic candidate; Janssen Pharmaceuticals, Inc., to develop nucleic-acid-based therapeutic candidates to treat hepatitis B; CureVac AG, Singapore Economic Development Board, and Duke-NUS Medical School in order to develop LUNAR-COV19, an anti-Coronavirus vaccine; Catalent, Inc. Arcturus Therapeutics Holdings Inc. is located in San Diego, California.

NASDAQ ended the session with Arcturus Therapeutics dropping 21.89% to $12.95 on Wednesday while NASDAQ fell 3.18% to $11,364.24.

Volume

Today’s last reported volume for Arcturus Therapeutics is 897106 which is 45.21% above its average volume of 617765.

Arcturus Therapeutics’s last close was $16.58, 74.49% below its 52-week high of $65.00.

Arcturus Therapeutics’s Sales

Arcturus Therapeutics’s sales growth is 607.3% for the current quarter and 2092.3% for the next. The company’s growth estimates for the ongoing quarter is a negative 34.4% and positive 95.8% for the next.

Arcturus Therapeutics’s Revenue

Year-on-year quarterly revenue growth grew by 4.5%, now sitting on 8.8M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Arcturus Therapeutics’s stock is considered to be overbought (>=80).

Arcturus Therapeutics’s Stock Yearly Top and Bottom Value

Arcturus Therapeutics’s stock is valued at $12.95 at 17:36 EST, way below its 52-week low of $16.93.

Arcturus Therapeutics’s Moving Average

Arcturus Therapeutics’s value is way below its 50-day moving average of $23.65 and way under its 200-day moving average of $35.95.

More news about Arcturus Therapeutics.

9. Kodak (KODK) – -21.81%

Eastman Kodak Company supplies hardware, software and consumables to worldwide customers in graphic arts, publishing, electronic display, entertainment, consumer goods, and other markets. It operates six business segments, including Print Systems, Enterprise Inkjet Systems Software and Solutions Consumer and Film Advanced Materials and 3D Printing Technology and Eastman Business Park. The company offers digital offset plates and computer-to plate imaging; inkjet components, services and consumables; as well as a range of software solutions to improve print production workflow. It also offers consumer inkjet printers as well as specialty inks or dispersions, industrial film and chemicals, as well as motion picture films. The Kodak brand is licensed to third parties for many products including digital, instant, disposable, and camera accessories as printers, LED lighting, and printers. It also offers intellectual property licensing and leases technology centre and industrial complex. It sells products and services via third-party resellers and distributors as well as direct and indirect to customers and enterprise accounts. Eastman Kodak Company, which was established in Rochester in New York in 1880, is still headquartered there.

NYSE ended the session with Kodak sliding 21.81% to $3.86 on Wednesday, after two sequential sessions in a row of losses. NYSE fell 0.82% to $14,902.14, after four sequential sessions in a row of losses, on what was a somewhat bearish trend trading session today.

Volume

Today’s last reported volume for Kodak is 3185000 which is 74.37% above its average volume of 1826480.

Kodak’s last close was $4.46, 60.39% below its 52-week high of $11.26.

Kodak’s Revenue

Year-on-year quarterly revenue growth grew by 13.9%, now sitting on 1.14B for the twelve trailing months.

Kodak’s Stock Yearly Top and Bottom Value

Kodak’s stock is valued at $3.86 at 17:36 EST, way under its 52-week high of $11.26 and way higher than its 52-week low of $3.46.

Kodak’s Moving Average

Kodak’s worth is way below its 50-day moving average of $5.55 and way under its 200-day moving average of $6.02.

More news about Kodak.

10. DISH Network (DISH) – -20.48%

DISH Network Corporation and its affiliates provide pay-TV services throughout the United States. It operates two business segments: Pay-TV, and Wireless. The company offers DISH TV video services. It also has programming packages which include national, regional, and local cable networks. It also offers access to TV and Internet-connected TVs, tablets and smartphones. The dishanywhere.com mobile application for tablets and smartphones allows you to remotely manage certain features, view approved content and search for program listings. It also offers Sling TV services such as Sling Latino and Sling Orange and Sling Blue. These services require an Internet connection, can be accessed on any streaming-capable device, like TVs and tablets. This is aimed at consumers who don’t subscribe to cable or satellite pay-TV. It had 11.986million Pay-TV subscribers as of December 31, 2019. It offers programming and receivers through small satellite retailers and direct sales channels. DISH Network Corporation was established in 1980. It is located in Englewood in Colorado.

NASDAQ ended the session with DISH Network falling 20.48% to $17.30 on Wednesday, following the last session’s upward trend. NASDAQ slid 3.18% to $11,364.24, following the last session’s upward trend on what was a very negative trend trading session today.

Volume

Today’s last reported volume for DISH Network is 17134000 which is 465.89% above its average volume of 3027760.

DISH Network’s last close was $21.75, 53.77% under its 52-week high of $47.05.

DISH Network’s Sales

DISH Network’s sales growth is 0.2% for the present quarter and a decline by 1.9% for the next. The company’s growth estimates for the present quarter and the next is a negative 24.2% and a negative 31.1%, respectively.

DISH Network’s Revenue

Year-on-year quarterly revenue growth declined by 1.8%, now sitting on 17.99B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

DISH Network’s stock is considered to be overbought (>=80).

DISH Network’s Stock Yearly Top and Bottom Value

DISH Network’s stock is valued at $17.30 at 17:37 EST, way below its 52-week low of $21.77.

DISH Network’s Moving Average

DISH Network’s worth is way under its 50-day moving average of $30.86 and way under its 200-day moving average of $36.11.

More news about DISH Network.

Stay up to date with our winners and losers daily report

LEAVE A REPLY

Please enter your comment!
Please enter your name here